Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB6IM8
|
|||
| Drug Name |
esamisulpride
|
|||
| Synonyms |
(S)-amisulpride; 71675-92-8; Amisulpride, (S)-; ES3TWM82E8; Benzamide, 4-amino-N-(((2S)-1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-; (S)-4-Amino-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; (S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; UNII-ES3TWM82E8; S-Amisulpride; ESAMISULPRIDE; S-(-)-Amisulpride; ESAMISULPRIDE [INN]; SCHEMBL675545; NTJOBXMMWNYJFB-LBPRGKRZSA-N; DTXSID301316207; EX-A5710; AKOS040747622; 4-amino-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide; AC-37136; MS-25938; HY-126068; CS-0090362; Q27277333; (S)-(-)-N-(1-ethyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-ethylsulphonylbenzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Bipolar disorder [ICD-11: 6A60; ICD-10: F31] | Phase 3 | [1] | |
| Company |
Sunovion Pharmaceuticals Marlborough, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H27N3O4S
|
|||
| Canonical SMILES |
CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
|
|||
| InChI |
InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)/t12-/m0/s1
|
|||
| InChIKey |
NTJOBXMMWNYJFB-LBPRGKRZSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05227209) A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression). U.S.National Institutes of Health. | |||
| REF 2 | Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders. Clin Pharmacol Ther. 2021 Sep;110(3):808-815. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.